These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25731442)

  • 1. [Postoperative cholangitis of balloon-occluded transarterial chemoembolization (B-TACE) for hepatocellular carcinoma].
    Okabe K; Beppu T; Komori H; Sano O; Yamanaka T; Haraoka K; Ouchida Y; Fujiyama S; Baba H
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2119-21. PubMed ID: 25731442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balloon-occluded transarterial chemoembolization using a 1.8-French tip coaxial microballoon catheter for hepatocellular carcinoma: technical and safety considerations.
    Matsumoto T; Endo J; Hashida K; Ichikawa H; Kojima S; Takashimizu S; Watanabe N; Yamagami T; Hasebe T
    Minim Invasive Ther Allied Technol; 2015 Apr; 24(2):94-100. PubMed ID: 25263680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
    Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
    Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
    Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.
    Koizumi Y; Hirooka M; Uehara T; Kisaka Y; Uesugi K; Kumagi T; Abe M; Matsuura B; Hiasa Y; Onji M
    Hepatogastroenterology; 2011; 58(106):512-5. PubMed ID: 21661422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial Experience with Balloon-Occluded Trans-catheter Arterial Chemoembolization (B-TACE) for Hepatocellular Carcinoma.
    Maruyama M; Yoshizako T; Nakamura T; Nakamura M; Yoshida R; Kitagaki H
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):359-66. PubMed ID: 26711804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure.
    Irie T; Kuramochi M; Takahashi N
    Cardiovasc Intervent Radiol; 2013 Jun; 36(3):706-13. PubMed ID: 22996589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balloon-Occluded Trans-Arterial Chemoembolization Technique with Alternate Infusion of Cisplatin and Gelatin Slurry for Small Hepatocellular Carcinoma Nodules Adjacent to the Glisson Sheath.
    Irie T; Takahashi N; Kamoshida T
    Biomed Res Int; 2019; 2019():8350926. PubMed ID: 31211142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial safety and outcomes of miriplatin plus low-dose epirubicin for transarterial chemoembolisation of hepatocellular carcinoma.
    Iwazawa J; Hashimoto N; Ohue S; Mitani T
    Anticancer Res; 2012 Nov; 32(11):5039-44. PubMed ID: 23155276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience.
    Minami Y; Minami T; Chishina H; Arizumi T; Takita M; Kitai S; Yada N; Hagiwara S; Tsurusaki M; Yagyu Y; Ueshima K; Nishida N; Murakami T; Kudo M
    Oncology; 2015; 89 Suppl 2():27-32. PubMed ID: 26584033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
    Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
    Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results.
    Lucatelli P; Ginnani Corradini L; De Rubeis G; Rocco B; Basilico F; Cannavale A; Nardis PG; Corona M; Saba L; Catalano C; Bezzi M
    Cardiovasc Intervent Radiol; 2019 Jun; 42(6):853-862. PubMed ID: 30843093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
    Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
    Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
    Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
    AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a safety index of transarterial chemoembolization for hepatocellular carcinoma to prevent acute liver damage.
    Hwang JI; Chow WK; Hung SW; Li TC; Cheng YP; Ho YJ; Lin CC
    Anticancer Res; 2005; 25(3c):2551-4. PubMed ID: 16080491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma.
    Miyayama S; Yamashiro M; Shibata Y; Hashimoto M; Yoshida M; Tsuji K; Toshima F; Matsui O
    Jpn J Radiol; 2012 Apr; 30(3):263-70. PubMed ID: 22223074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balloon-occluded arterial stump pressure before balloon-occluded transarterial chemoembolization.
    Matsumoto T; Endo J; Hashida K; Mizukami H; Nagata J; Ichikawa H; Kojima S; Takashimizu S; Yamagami T; Watanabe N; Hasebe T
    Minim Invasive Ther Allied Technol; 2016; 25(1):22-8. PubMed ID: 26406612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
    Matsumoto T; Ichikawa H; Imai J; Hayashi T; Tomita K; Mine T; Kojima S; Watanabe N; Hasebe T
    Anticancer Res; 2017 Jun; 37(6):3183-3187. PubMed ID: 28551662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
    Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
    Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.